Cancer Therapy: Monoclonal Antibodies, Lymphokines New Developments in Surgical Oncology and Chemo- And Hormonal Therapy

ISBN-13: 9783642737237 / Angielski / Miękka / 2011 / 308 str.

Hans G. Beger; Markus B. Chler; Ralph A. Reisfeld

Opis

A variety of new cancer therapy modalities are discussed and evaluated in this book. It aims to demonstrate that the combination of classical chemo- and radiotherapy with new approaches in the field of immunotherapy can result in an improved treatment modality. Immunotherapy in this context consists of therapy with monoclonal antibodies, hematopoietic growth factors and other lymphokines. Results of early clinical trials with IL-2, GM-CSF and monoclonal antibodies against gastrointestinal tumors and melanoma are included. The progress in regional chemotherapy strategies, for example of the liver, is shown. In addition, the development of new chemotherapeutic agents with a different mode of action as well as better tolerability is presented. The use of hormones, such as LH-RH agonists, allows hormone-dependent tumors such as prostatic and breast cancer to be treated without strong adverse reactions. These recent findings give the reader insight into exciting therapeutic directions made possible by such combined, rather than single, modalities.

Spis treści

Monoclonal Antibodies.- Immunochemotherapy of Cancer: A Perspective.- Quantitative Considerations Supporting the Irrelevance of Circulating Serum Carcinoembryonic Antigen for the Immunoscintigraphic Visualization of Carcinoembryonic Antigen-Expressing Carcinomas.- Radioimmunotherapy with Iodine 131-Labelled Antibodies in Ovarian, Colonic and Brain Tumours.- Radioimmunodetection and Radioimmunotherapy in Myosarcoma.- Immunotherapy of Pancreatic Cancer with Monoclonal Antibody BW 494: Results from a Multicentric Phase I–II Trial.- Mab 17-1A Used for Therapy of Patients with Metastatic Colorectal Carcinomas.- Immunotherapy of Malignant Melanomas.- Interaction of Monoclonal Antibodies with Biological Response Modifiers and Cytostatics.- Lymphokines.- Cancer Treatment with Cytokines: Concepts and First Clinical Experience.- Low-dose Cyclophosphamide and IL-2 in the Treatment of Advanced Melanoma.- Application of Granulocyte-Macrophage Colony-Stimulating Factor in Patients with Malignant Hematological Diseases.- Enhancement of Autologous Bone Marrow Transplantation with Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor (rhGM-CSF).- A Phase lb Evaluation of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor.- The Role of Interferon in the Management of Patients with Hairy Cell Leukemia and Multiple Myeloma.- Possible Mechanism of Interferon Action in Hairy Cell Leukemia.- Tumor Vaccination in the Treatment of Colorectal Cancer.- New Approaches in Surgical Oncology.- New Developments in Surgical Oncology.- Cancer Surgery — Conservative or Radical?.- Regional Chemotherapy of the Liver and Hepatic Artery Occlusion.- Regional Chemotherapy of Hepatic Metastases.- Regional Chemotherapy in Hepatic Metastases of Colorectal Carcinoma: Continuous Intra-arterial Versus Continuous Intra-arterial/Intravenous Therapy.- Isolated Regional Hyperthermal Liver Perfusion: Indications, Technique and Results.- Chemoembolization of Liver Tumors.- New Cancer Treatment with Lasers - Photodynamic Therapy and Interstitial Hyperthermia.- Specificity, Kinetics, and Distribution of Monoclonal Antibodies to Carcinoembryonic Antigen in Human Colorectal Carcinoma by Ex Vivo Human Tumor Perfusion.- Chemotherapy and Hormonal Therapy.- Chemotherapy: Benefits and Limits.- The Human Tumor Clonogenic Assay for the Prediction of Tumor Sensitivity.- Chemosensitivity: Directed Regional Chemotherapy of Liver Metastases.- Clinical Development of New Anthracyclines.- First Clinical Experience with Cytorhodin S - The First Compound of a New Class of Anthracyclines.- Pirarubicin: A New Drug in the Treatment of Malignant Diseases.- Pirarubicin — A New Anthracycline with High Activity in Untreated Patients with Small-Cell Cancer of the Lung.- New Approaches in the Hormonal Therapy of Breast Cancer..- Reproductive Toxicity with and Without Administration of Luteinizing-Hormone-Releasing Hormone Agonist During Adjuvant Chemotherapy in Patients with Germ Cell Tumors.

O autorze

Markus Büchler ist leitender Psychologe einer psychologischen Beratungsstelle und Psychotherapeut. Er verfügt über jahrelange Erfahrungen als Lehrbeauftragter der Musikhochschule, als Musiklehrer und als künstlerisch tätiger Musiker nach einem künstlerischen Hochschulstudium.